Skip to main content

Table 1 Observed parasitaemia in Pk4 vaccinated, CSP/SSP2 vaccinated and control (mock vaccine) groups.

From: Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques

Experiment #

Vaccine group

Rhesus ID

day1stparasitaemia

Mean 1stday parasitaemia

day >1.5% parasitaemia

Mean day >1.5% parasitaemia

1

Mock*

20H

7

7.0

12

11.5

1

Mock

205

7

 

12

 

1

Mock

AB07†

7

 

11

 

1

Mock

AB58

7

 

12

 

1

Mock

Q121

7

 

11

 

2

csp/ssp2

IIG

9

8.2

11

11.2

2

csp/ssp2

AB67

8

 

11

 

2

csp/ssp2

AC70

8

 

12

 

2

csp/ssp2

Q134

8

 

10

 

2

csp/ssp2

AK52

8

 

12

 

2

csp/ssp2

IIG

9

 

11

 

2

Pk4**

281

11

9.5

14

13

2

Pk4

284

9

 

13

 

2

Pk4

3000

9

 

13

 

2

Pk4

3129

9

 

13

 

2

Pk4

19159

9

 

13

 

2

Pk4

262

9

9.5

Never

Never

2

Pk4

299

10

 

Never

 

2

Pk4

3086

11

 

Never

 

2

Pk4

3098

9

 

Never

 

2

Pk4

AB34

9

 

Never

 

1

Pk4

Q120

9

 

Never

 

1

Pk4

T152

10

 

Never

 

3

Pk4

228

10

 

Never

 
  1. † Animal died before the end of the study. No post challenge sample was available.
  2. * Mock, vaccine comprised of empty DNA vector and empty COPAK vaccinia virus
  3. ** Pk4, vaccine comprised of four Plasmodium knowlesi antigens, csp/ssp2/ama1/msp142
  4. Day to 1st parasitaemia is the day of patency of parasites on thin smear. Day >1.5% parasitaemia is the day of drug treatment. All vaccinated animals were primed with 3 DNA vaccine injections and boosted with recombinant poxviruses encoding the Pk4 antigens. Control (mock) animals received mock DNA vaccine and empty poxvirus. Subjects were taken from three experiments (#1-3), under identical vaccination regimens.